About

Dr. Greg Gin is a urologic surgeon and researcher whose work centers on advancing surgical treatments for benign prostatic hyperplasia (BPH) and renal malignancies. He is best known for his pivotal role in the development and long-term validation of Aquablation therapy, a minimally invasive waterjet ablation technique for treating lower urinary tract symptoms due to BPH. His landmark publications, including the 1-year and 5-year results of the WATER II clinical trial (cited over 110 times collectively), established the safety and durability of Aquablation for large prostates (80–150 cc), offering a transformative option for patients with complex anatomy. Beyond BPH, Dr. Gin has made significant contributions to renal surgery, comparing perioperative outcomes of retroperitoneal versus transperitoneal partial nephrectomy and evaluating surgical approaches for very large renal masses. His work on ureteroenteric anastomotic revision as an initial management strategy for strictures after urinary diversion has also informed clinical practice. With over 200 total citations, Dr. Gin’s research bridges innovation and evidence-based practice, directly improving surgical outcomes for patients with urologic conditions.

Research Focus

Key Achievements

5
H-Index
6
Papers
213
Total Citations
36
Avg Citations/Paper
🏆 Most Cited Paper
Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results
63 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 49
🏛 Institutions: VA Long Beach Healthcare System, Mount Sinai Hospital, City Of Hope National Medical Center, University of California, Irvine

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago